Endometriosis occurs when tissue similar to that normally found in the uterus begins to grow outside of the uterus, leading to a range of symptoms, including painful periods, pelvic pain in between periods, and pain with sex. These growths are called lesions and can occur on the ovaries, the fallopian tubes, or other areas near the uterus, such as the bowel or bladder. Estrogen fuels the growth of lesions.
According to researchers, 7.5 million women in the United States are diagnosed with endometriosis, with 3 million diagnosed with moderate to severe endometriosis.
In collaboration with AbbVie, Neurocrine Biosciences has a novel, oral treatment approved for the management of moderate to severe endometriosis pain. AbbVie is responsible for all development, marketing, and commercialization costs.
Uterine fibroids are benign (non-cancerous) growths that form inside, outside, or in the wall of the uterus. They are most often seen in women between the ages of 30-40 but can occur at any age. Uterine fibroids are the most common pelvic growth affecting around 20 percent of all women by age 59. Uterine fibroids are the leading cause of infertility.
Some common symptoms associated with uterine fibroids include heavy menstrual bleeding, painful periods, vaginal bleeding at times other than menstruation, anemia, pain in the abdomen or lower back, pain during sex, difficulty urinating or frequent urination, constipation, rectal pain, or difficulty getting pregnant.
In collaboration with AbbVie, Neurocrine Biosciences has a novel, oral treatment approved by the U.S. FDA for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. AbbVie is responsible for all development, marketing, and commercialization of the treatment.